Trends in the Evaluation of Biotech Development Candidates

Rubrik: Fachthemen

(Treffer aus pharmind, Nr. 09, Seite 1396 (2014))

Thunecke M | Botschen F

Trends in the Evaluation of Biotech Development Candidates / The method of choice · Thunecke M, Botschen F · Catenion, Berlin, Germany
Seven Major Markets (US, Japan, Germany, France, UK, Spain, Italy) Costs of Goods Food and Drug Administration (US) Health Technology Assessment Incremental cost-effectiveness ratio Likelihood of Approval National Institute for Health and Care Excellence (UK) New Molecular Entity Net Present Value Overall Survival Option Space Mapping Proof of Concept Standard of Care Target Product Profile Venture Capital When one talks to investors active in the biotech sector, it is widely acknowledged that drug development is a risky business with high reward potential but also large sums to be lost. While many pharma companies can mitigate risk by building a sufficiently ...